El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

846678.pdf (1.1 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2024-03-01

Llicència de publicació

cc-by-nc-nd (c) Elsevier Ltd, 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209827

Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/S2215-0366(24)00006-3

Resum

Background: There are no recommendations based on the efficacy of specific drugs for the treatment of psychotic depression. To address this evidence gap, we did a network meta-analysis to assess and compare the efficacy and safety of pharmacological treatments for psychotic depression. Methods: In this systematic review and network meta-analysis, we searched ClinicalTrials.gov, CENTRAL, Embase, PsycINFO, PubMed, Scopus, and Web of Science from inception to Nov 23, 2023 for randomised controlled trials published in any language that assessed pharmacological treatments for individuals of any age with a diagnosis of a major depressive episode with psychotic features, in the context of major depressive disorder or bipolar disorder in any setting. We excluded continuation or maintenance trials. We screened the study titles and abstracts identified, and we extracted data from relevant studies after full-text review. If full data were not available, we requested data from study authors twice. We analysed treatments for individual drugs (or drug combinations) and by grouping them on the basis of mechanisms of action. The primary outcomes were response rate (ie, the proportion of participants who responded to treatment) and acceptability (ie, the proportion who discontinued treatment for any reason). We calculated risk ratios and did separate frequentist network meta-analyses by using random-effects models. The risk of bias of individual studies was assessed with the Cochrane risk-of-bias tool and the confidence in the evidence with the Confidence-In-Network-Meta-Analysis (CINeMA). This study was registered with PROSPERO, CRD42023392926.

Matèries

Depressió psíquica, Medicaments, Metaanàlisi, Ressenyes sistemàtiques (Investigació mèdica), Antipsicòtics, Antidepressius

Matèries (anglès)

Mental depression, Drugs, Meta-analysis, Systematic reviews (Medical research), Antipsychotic drugs, Antidepressants

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

OLIVA, Vincenzo, POSSIDENTE, Chiara, DE PRISCO, Michele, FICO, Giovanna, ANMELLA, Gerard, HIDALGO MAZZEI, Diego, MURRU, Andrea, FANELLI, Giuseppe, FABBRI, Chiara, FORNARO, Michele, DE BARTOLOMEIS, Andrea, SOLMI, Marco, RADUA, Joaquim, VIETA I PASCUAL, Eduard, SERRETTI, Alessandro. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis. _The Lancet Psychiatry_. 2024. Vol. 11, núm. 3, pàgs. 210-220. [consulta: 25 de desembre de 2025]. ISSN: 2215-0366. [Disponible a: https://hdl.handle.net/2445/209827]

Exportar metadades

JSON - METS

Compartir registre